By Ian Walker

AstraZeneca PLC said Thursday that its Covid-19 antibody combination Evusheld retains neutralization activity against the Omicron SARS-CoV-2 variant.

The drug major said the result follows a study independently performed by investigators at the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research.

It added that extra analysis to evaluate Evusheld against the Omicron variant are being conducted by AstraZeneca and third-party laboratories, with data anticipated very soon.

"Evusheld is the first long-acting antibody to receive emergency use authorization in the U.S. for pre-exposure prophylaxis of Covid-19, in addition to authorizations in other countries, and we are working with regulators on applications for the use of Evusheld in treating Covid-19," said Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca.

Shares at 1423 GMT were up 102.0 pence, or 1.2%, at 8,391.0 pence.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

December 16, 2021 09:46 ET (14:46 GMT)

Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2022 até Mai 2022

Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mai 2021 até Mai 2022